Navigation Links
QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
Date:3/31/2009

ANN ARBOR, Mich., March 31 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company, today announced that it has completed enrollment in the Company's second pivotal Phase 3 clinical trial of Ophena(TM) (ospemifene tablets). Together with the previously completed first pivotal Phase 3 study of Ophena(TM), the Company has fully enrolled its planned pivotal Phase 3 studies for Ophena(TM), the most advanced estrogen-free oral therapy currently in development for the treatment of vaginal symptoms associated with menopause. A total of more than 1,700 patients were enrolled in these two pivotal studies at sites across the U.S. In accordance with the study design, all enrolled patients have received their first dose of either Ophena(TM) or placebo in the second Phase 3 clinical trial. Due to the high level of interest from patients and physicians, the Company chose to exceed its enrollment target of 750 patients. The Company expects to complete the study in late summer-2009 and these data, together with results from the first phase 3 study, will complete the efficacy requirements for an NDA filing under the published FDA guidance for vaginal atrophy.

"We are pleased to have achieved this important development milestone in the development of Ophena(TM) and to have exceeded our enrollment goal in only seven months, in what we believe to be the largest vaginal atrophy study ever conducted," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx. "We believe that the high interest in this study indicates a substantial need for new therapies for the treatment of postmenopausal vaginal atrophy."

The randomized, double-blind study has enrolled over 900 postmenopausal women at 116 trial centers throughout the United States. Women in the study are being treated with either a 60mg once daily oral dose of Ophena(TM) or placebo over the 12-week trea
'/>"/>

SOURCE QuatRx Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
4. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Synereca Pharmaceutics, ... novel orally active drugs that restore or ... today a $1.4 million convertible debt financing. ... life sciences accelerator Accele Biopharma, Inc., led ... a nationally recognized private not-for-profit corporation focused ...
(Date:9/16/2014)... Alberta , Sept. 16, 2014  Wearable ... billion industry in less than two years, producing ... the way. A huge opportunity exists for leveraging ... Vivametrica ( http://vivametrica.com/our-video/ ) introduced a first-of-its-kind wearable ... based on years of clinical research linking activity ...
(Date:9/16/2014)... , Sept. 16, 2014  Eli Lilly ... AstraZeneca today announced an agreement to co-develop and ... (BACE) inhibitor currently in development as a potential ... of Alzheimer,s disease is characterized by the accumulation ... an enzyme associated with the development of beta-amyloid. ...
Breaking Medicine Technology:Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 2Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 3Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners 4Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 2Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 3Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease 4
... NEW YORK, July 19, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0574366/World-Healthcare-UPS-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices This ... healthcare UPS market, examining drivers and restraints ...
... INDIANAPOLIS, July 19, 2011 Data were presented today ... semagacestat, including data from a 32 week follow-up period ... a gamma secretase inhibitor that had been studied as ... provided patient outcomes from the active treatment portion of ...
Cached Medicine Technology:World Healthcare UPS Markets 2World Healthcare UPS Markets 3World Healthcare UPS Markets 4World Healthcare UPS Markets 5World Healthcare UPS Markets 6Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research 2Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research 3Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research 4
(Date:9/16/2014)... CA (PRWEB) September 16, 2014 According to ... player David Wilson has retired after aggravating a neck injury ... and was then discovered to have spinal stenosis as well, ... many adults and can lead to symptoms such as back ... play again after surgery to repair the disc, but recently ...
(Date:9/16/2014)... September 16, 2014 According to ... Research "Latin America Home Healthcare Market (By Device ... Devices, Mobility Assist Devices and Medical Supplies; By ... Therapy and Unskilled Home Healthcare Services) - Industry ... - 2020" the Latin American Home Healthcare market ...
(Date:9/16/2014)... 2014 Today The FSH Society, a world ... Evening of Song,” featuring luminary pianist Steven Blier and two-time ... September 29, 2014 at the Tappan Hill Mansion, located on ... FSH Society is proud to welcome Blier, who performs each ... for FSHD research. , FSHD, one of the most prevalent ...
(Date:9/16/2014)... 16, 2014 Luke Sniewski, Claire Robbie ... a 14-month journey around the world to celebrate cultural ... project, titled ‘Million Ways to Live’, will take them ... the healthy lifestyles of amazing, unique and diverse people. ... the documentary series will focus on how individuals apply ...
(Date:9/16/2014)... September 16, 2014 According to a ... global authority in medical device market research, the market ... $750 million in the U.S . and ... PEG placement kits, PEG replacement tubes, DPEJ tubes, PEG/J ... into low-profile balloon tubes, low-profile non-balloon tubes, nasogastric and ...
Breaking Medicine News(10 mins):Health News:NFL Injuries Put Spotlight on Spinal Health 2Health News:NFL Injuries Put Spotlight on Spinal Health 3Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Health News:Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 2Health News:Pianist Steven Blier and Grammy Award-Winner Sylvia McNair to Perform Together for FSH Society Benefit 3Health News:Launched by Luke Sniewski and Claire Robbie, Million Ways to Live is an International Documentary Series on Healthy Living in Different Cultures 2Health News:Launched by Luke Sniewski and Claire Robbie, Million Ways to Live is an International Documentary Series on Healthy Living in Different Cultures 3Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 2Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 3
... passive smoke could face a higher heart disease risk, says ... second hand smoke exposure through levels of a nicotine by-product ... on the participants' recall of exposure. ,However, in ... of Nottingham, and other researchers measured the level of cotinine ...
... linked to many of the same health problems as tobacco ... wheeze, according to a new study by researchers at Yale ... widely used illicit drug in the United States, and abuse ... published in today’s Archives of Internal Medicine. First author Jeanette ...
... treating atrial fibrillation, a common irregular heart rhythm that ... of Medicine in St. Louis have developed and tested ... surgical procedure that has had the best long-term cure ... procedure is termed Cox-maze IV, and the surgeons believe ...
... migrant birds will be outstaying their welcome in north and central ... has called for tougher measures on bird flu prevention, especially in ... this time, there is an increase in transportation of livestock and ... is predominant during this season. , Yin ...
... that aids patients who suffer from persistent iron overload has ... ,Patients suffering from a rare genetic condition or conditions ... Generally these people are given a painful infusion at nights ... ,But the new drug Exjade is an oral ...
... stress hormone cortisol can have positive effects in certain ... cortisol in the bloodstream, can weaken the immune system ... evidence that cortisol given near in time to a ... impact. ,Psychologists are especially interested in what ...
Cached Medicine News:Health News:Long-term Marijuana Smoking Leads to Respiratory Complaints 2Health News:Surgeons Develop Simpler Way to Cure Atrial Fibrillation 2Health News:Extra Cortisol Protects Women’s Mood Under Stres 2
Steinmann Pins are available in six point styles ranging from 5/64 to 3/16 in. diameters, in standard 9 in. (230 mm) lengths with threaded and smooth tips. Material: DePuy certified stainless steel. ...
... is the only approved radiolucent stand-alone implant ... with the proven reliability of the BAK ... System is constructed of radiolucent, carbon-fiber reinforced ... radiologic visualization, providing a new level of ...
... (Western Blot): The Genetic Systems HIV-1 Western ... the detection of antibodies to HIV-1. The solid ... HIV-1 grown in the CEM cell line. Use ... of HLA Class ll antigens, helps reduce cross ...
... HIV-1 RNA Assay (bDNA) delivers unmatched precision and ... providing physicians with viral load values they can ... and at other critical decision points - without ... need more reasons to choose VERSANT HIV bDNA, ...
Medicine Products: